The stock of Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) is a huge mover today! The stock decreased 1.72% or $0.21 during the last trading session, reaching $12. About 176,723 shares traded or 175.22% up from the average. Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.The move comes after 8 months negative chart setup for the $380.61 million company. It was reported on Feb, 15 by Barchart.com. We have $10.92 PT which if reached, will make NASDAQ:CMTA worth $34.25M less.
Among 8 analysts covering NIC (NASDAQ:EGOV), 1 have Buy rating, 1 Sell and 6 Hold. Therefore 13% are positive. NIC had 17 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “In-Line” rating by Imperial Capital given on Friday, November 18. The stock of NIC Inc. (NASDAQ:EGOV) earned “Buy” rating by Imperial Capital on Monday, July 17. As per Friday, August 5, the company rating was maintained by Maxim Group. The company was maintained on Wednesday, November 18 by Imperial Capital. Zacks upgraded the shares of EGOV in report on Monday, August 24 to “Sell” rating. The rating was downgraded by Stephens on Monday, August 17 to “Overweight”. The rating was downgraded by Avondale to “Mkt Underperform” on Thursday, February 2. Sidoti downgraded the shares of EGOV in report on Friday, July 21 to “Hold” rating. Avondale downgraded the shares of EGOV in report on Friday, February 5 to “Market Perform” rating. As per Wednesday, February 15, the company rating was initiated by Loop Capital. See NIC Inc. (NASDAQ:EGOV) latest ratings:
01/02/2018 Broker: Stephens Rating: Hold New Target: $14.0 Maintain
Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. The company has market cap of $380.61 million. The Company’s lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models. It currently has negative earnings. The firm is developing palovarotene for the treatment of fibrodysplasia ossificans progressiva and multiple osteochondroma, as well as has one Phase III and Phase II/III trials for two separate indications.
Investors sentiment decreased to 1.41 in 2017 Q3. Its down 0.24, from 1.65 in 2017Q2. It fall, as 25 investors sold NIC Inc. shares while 45 reduced holdings. 30 funds opened positions while 69 raised stakes. 60.61 million shares or 0.50% more from 60.31 million shares in 2017Q2 were reported. Creative Planning invested 0% of its portfolio in NIC Inc. (NASDAQ:EGOV). Tiaa Cref Invest Ltd Liability holds 0% in NIC Inc. (NASDAQ:EGOV) or 170,217 shares. U S Glob Investors Incorporated invested in 0.31% or 48,911 shares. Ameriprise has invested 0% of its portfolio in NIC Inc. (NASDAQ:EGOV). Oppenheimer Asset Mngmt holds 0% of its portfolio in NIC Inc. (NASDAQ:EGOV) for 310 shares. Ahl Llp has invested 0.02% in NIC Inc. (NASDAQ:EGOV). Deutsche Fincl Bank Ag holds 0% of its portfolio in NIC Inc. (NASDAQ:EGOV) for 356,684 shares. Principal Financial Gru holds 0.01% in NIC Inc. (NASDAQ:EGOV) or 534,655 shares. Thrivent Fincl For Lutherans has 40,793 shares for 0% of their portfolio. Credit Suisse Ag owns 0% invested in NIC Inc. (NASDAQ:EGOV) for 96,080 shares. New York-based Pinebridge Invests Lp has invested 0% in NIC Inc. (NASDAQ:EGOV). Moreover, Conestoga Advisors Limited Liability Corp has 1.53% invested in NIC Inc. (NASDAQ:EGOV). Thompson Siegel & Walmsley Ltd Limited Liability Company invested in 0% or 2,000 shares. Copeland Cap Management Limited Liability Corp stated it has 565,970 shares or 0.66% of all its holdings. State Board Of Administration Of Florida Retirement System reported 0% stake.